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Background: The most important means of identifying diseases before symptoms appear is through the discovery
of disease-associated biomarkers. Recently, microRNAs (miRNAs) have become highly useful biomarkers of infectious,
genetic and metabolic diseases in human but they have not been well studied in domestic animals. It is probable
that many of the animal homologs of human disease-associated miRNAs may be involved in domestic animal
diseases. Here we describe a computational biology study in which human disease miRNAs were utilized to predict
orthologous miRNAs in cow, chicken, pig, horse, and dog.
Results: We identified 287 human disease-associated miRNAs which had at least one 100% identical animal
homolog. The 287 miRNAs were associated with 359 human diseases referenced in 2,863 Pubmed articles. Multiple
sequence analysis indicated that over 60% of known horse mature miRNAs found perfect matches in human
disease-associated miRNAs, followed by dog (50%). As expected, chicken had the least number of perfect matches
(5%). Phylogenetic analysis of miRNA precursors indicated that 85% of human disease pre-miRNAs were highly
conserved in animals, showing less than 5% nucleotide substitution rates over evolutionary time. As an example we
demonstrated conservation of human hsa-miR-143-3p which is associated with type 2 diabetes and targets AKT1
gene which is highly conserved in pig, horse and dog. Functional analysis of AKT1 gene using Gene Ontology (GO)
showed that it is involved in glucose homeostasis, positive regulation of glucose import, positive regulation of
glycogen biosynthetic process, glucose transport and response to food.
Conclusions: This data provides the animal and veterinary research community with a resource to assist in
generating hypothesis-driven research for discovering animal disease-related miRNA from their datasets and
expedite development of prophylactic and disease-treatment strategies and also influence research efforts to
identify novel disease models in large animals. Integrated data is available for download at http://agbase.hpc.
msstate.edu/cgi-bin/animal_mirna.cgi.
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MicroRNAs (miRNAs) are naturally occurring single-
stranded small RNA molecules that play important roles
in post-transcriptional regulation of gene expression [1].
Studies have shown that miRNAs exert their regulatory
role by partially binding their target (complementary)
mRNAs at 3′ UTRs (untranslated regions) [2-5]. Phylo-
genetic studies indicate that animal miRNAs are highly
conserved [6,7]. Until recently, miRNAs were thought to* Correspondence: tbuza@cvm.msstate.edu
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unless otherwise stated.be of little or no cellular significance [8-10]. The first
miRNA shown to have a regulatory function was lin-4
from Caenorhabditis elegans [11,12]. Lin-4 acted as a silen-
cer of genes that regulate developmental timing, but it was
considered a unique evolutionary adaptation as lin-4 ho-
mologs were not found in other species. The discovery of
the regulatory miRNA let-7 in C. elegans in 2000 [10], with
homologs in other species including humans, caused re-
searchers to reconsider the idea that miRNAs may have a
more widespread function within cells. We now know that
many miRNAs play central roles in post-transcriptional
gene regulation. Additionally, expression of specific
miRNAs has been linked to various diseases [13-16].
Considerable research has been devoted to understandingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and miRNAs are important biomarkers of several disease
processes [27-32] including many cancers [33-43] and
cardiovascular [18,44-53], inflammation [54-57], and gas-
trointestinal diseases [58-60].
While databases for human disease-associated miRNAs
are publicly available [61-70], there is no any integrated
resource for disease-associated miRNAs in domestic
animals. An integrated resource of animal disease-related
miRNA data would provide the animal and veterinary
research community with an invaluable resource for
searching disease related miRNA subsets from their
experimental data. Pubmed articles stand solely as the
major reliable source of information for disease miRNA
data. However, there are very few Pubmed articles currently
(as of 12/31/2014) documenting disease-associated miRNAs
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Figure 1 Publication statistics of disease associated miRNAs as of 12/
conditioned to retrieve publications from the last ten years. The searches c
(year). For example searching Pubmeds for dog disease associated miRNAs in
(dog OR canine OR (Canis familiaris) AND (microRNA OR microRNAs OR miRN
diseases OR disorder OR disorders) AND ((“2004/01/01”[PDat] : “2013/12/31”[P
large difference in number of Pubmed articles.(Figure 1). Identification of miRNA/disease associations in
domestic animals is critical for understanding miRNA
involvement in the pathophysiology of these organisms.
The main objective of our study was to identify animal
miRNA homologs of published human disease-associated
miRNAs in cow, chicken, pig, horse and dog using phylo-
genetic techniques. Using the current available human
and animal miRNA resources, we identified potential
disease-related miRNAs in domestic animals based on
integrated computational and manual approaches includ-
ing assessing the sequence similarities and evolutionary
relationships between human disease miRNAs and their
animal orthologs. These predictions will serve as a re-
source to facilitate hypothesis-driven research in domestic
animals, which upon verification in animals could suggest
animal models for human diseases and strategies for










31/2013. Searches from NCBI-Pubmed titles or abstracts were
ontained species names, miRNA abbreviations, disease(s) and duration
the past 10 years were acquired using the following query statement:
A OR mirRNAs OR mir OR miRs) AND (cancer OR cancers OR disease OR
Dat])). Note that (A) and (B) are presented in different y-axis scale due to
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Human and domestic animal mature miRNA sizes
We compared the sizes of all known mature human
miRNAs with the sizes of all known cow, chicken, pig,
horse, and dog to establish their length diversity.
Extraction and verification of disease-associated human
miRNAs
Briefly, we surveyed publicly available databases that link
human miRNAs with diseases [65,67,71,72] and selected
the most up-to-date and comprehensive human disease
miRNA database, i.e., the Human miRNA Disease Data-
base (HMDD) version 2.0 [58], as a baseline for search-
ing animal homologs. We then filled a request form
available at http://202.38.126.151/hmdd/html/tools/hmdd_
req.html to request all human disease-associated miRNA
data from Dr. Qinghua Cui of department of Biomedical
Informatics, Peking University Health Science Center.
From this data we retrieved the miRNA IDs (identifiers)
that were named according to miRBase [73] nomenclature
standards, the disease(s) associated with each miRNA and
the Pubmed articles from which the HMDD data was
extracted. We then manually reviewed the Pubmed titles
and abstracts to verify association of the miRNAs with
human diseases.
Prediction of animal homologs of human
disease-associated miRNAs
We used the IDs of human disease miRNAs (from
HMDD) to extract corresponding mature (i.e., processed)
miRNA nucleotide sequences from miRBase version 20
[73]. We also downloaded all sequences of mature and
precursor (pre) miRNAs for cow, chicken, pig, horse and
dog from miRBase version 20 and then used a Perl script
to identify cow, chicken, pig, horse, and dog mature
miRNA sequences that were 100% identical to sequences
of human disease-associated miRNAs. The outputs of the
Perl script were deemed “human disease miRNAs with
animal counterparts” (HDMACs).
Phylogenetic analysis of HDMAC precursor sequences
The precursor miRNA sequences (pre-miRNAs) of
HDMACs were compared using a multiple alignment
and phylogenetic approach to detect conservation pro-
files and rapid sequence divergence in human and do-
mestic animals. Briefly, we used Clustal Omega [74] tool
for multiple alignment of pre-miRNA sequences and
Clustalw2-Phylogeny tool [75] to generate the Neighbor-
Joining (NJ) phylogenetic trees to determine nucleotide
substitutions that have occurred over evolutionary time.
Briefly, NJ method compares each sequence with each
other, calculates distance matrices, then combines the
least distant pair of sequences and construct phylogenetic
tree. We displayed distances (divergence proportions)calculated from all pairs of sequences in the multiple
alignments to facilitate evolutionary interpretation of
phylograms. Divergence proportions less or equal to 5%
(≤0.05) were considered to be highly conserved.
Annotation of human disease miRNA targets and their
animal orthologs
We manually annotated the genes targeted by the human
disease-associate miRNAs from the associated Pubmed
articles and predict their animal orthologs using the
Ensembl Biomart [76] tool. All human targets and their
animal orthologs with one-to-one matches and reciprocal
% identity >70 were integrated in the animal disease
miRNA resource.
Integration of disease information with human-animal
miRNA homologs
We integrated the information gathered from this study
to form a computationally predicted animal disease miRNA
resource which contained miRNA information including
standardized miRBase identifiers of mature miRNAs, pre-
miRNAs, and miRNA families linked to the associated
human disease. Whenever applicable we used OMIM
(Online Mendelian Inheritance in Man) [77], OMIA
(Online Mendelian Inheritance in Animal) [78] and Dis-
ease Ontology (DO) [79] standardized names for disease
phenotypes and BRENDA (BRaunschweig ENzyme DAta-
base) Tissue Ontology (BTO) [80,81] terms to standardize
names of source tissues or cell types. Pubmed IDs were
used as central literature references. Additional informa-
tion regarding the genomic location(s) of miRNAs, type of
experiment, and publication date was also integrated.
Results
Lengths of animal and human mature miRNAs
Generally, the distribution of mature miRNA lengths in
all species followed same trend, with 22-nt sequences
dominating in each species (Figure 2).
Dataset of human disease-associated miRNAs
After surveying various human disease-related miRNA
databases, we found that the miRNAs in the Human
miRNA Disease Database (HMDD) version 2.0 [71] (up-
dated on 09/30/2013) were best suited for use as a training
set (Figure 3). This database contained 578 published
human miRNAs associated with 383 diseases referenced
in 3,486 Pubmed articles. The human disease miRNA
referenced in HMDD included 70% of the total 4,961
human disease miRNA articles we identified in Pubmed
(Figure 1).
We identified 694 domestic animal mature miRNA
sequences that showed 100% sequence identity with the
287 human disease miRNAs (Figure 4, Additional file 1).




















Figure 2 An overall distribution of sequence lengths of mature miRNAs. The length corresponds to the number of nucleotides in a miRNA
sequence.
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followed by dog (50%). As expected, chicken had the
least number of perfect matches (5%), most likely a result
of the relative evolutionary distance between birds and
mammals. We found that 14 human disease miRNAs
were conserved in all animals, chicken included, while 41


















Figure 3 Statistics of human disease miRNA databases as of 12/31/2013.Conserved human disease pre-miRNAs in animals
In addition to producing multiple alignments of mature
miRNAs, we established additional evolutionary relation-
ship between pre-miRNAs of HDMACs, which included
265 and 649 human and animal pre-miRNA sequences, re-
spectively. About 85% of human disease pre-miRNAs were
found to be highly conserved in animals, showing less than






































Non-HDMAC miRNAs for selected
animal
HDMACs with no known counterpart in
selected animal
HDMACs for selected animal
Figure 4 Mature human disease miRNA with animal counterparts (HDMACs) in key domestic animals. For a particular human-animal pair,
blue bar indicates HDMACs in other animals but not in the selected animal, red bars indicates HDMACs in the select animal and blue & red bars
together represent 287 HDMACs. Green sub-bars show non-HDMACs.
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analysis of pre-miRNA sequences of HDMACs that are
clustered in the mir-154 family (Figure 6). In this family
all pre-miRNAs had nucleotide substitution rate of <4%,
among which, pre-miRNA sequences of eight animals; 4
in horse (eca-mir 409, 494, 377 & 382), 2 in dog (cfa-mir-
494 & 377) and 2 in cow (bta-mir-377 & 382) had 100%
percent identity with 4 of human disease pre-miRNAs
sequences.
Animal orthologs of human disease miRNA targets
Genes targeted by the human disease-associated miRNAs
were utilized to predict their animal orthologs using the
Ensembl Biomart [76] tool. Currently, over 45 targets
conserved across human and domestic animals are inclu-
ded in the integrated resource available through AgBase
[82,83] at http://agbase.hpc.msstate.edu/cgi-bin/animal_
mirna.cgi. Example of conserved disease miRNA targets
linked to type 2 diabetes is included in this article
(Figure 7, Table 2) and more targets are shown as
Additional file 3.
Data integration
In order to provide a unified view of data generated
from this study we integrated all information to form a
core resource of domestic animal disease-related miR-
NAs. The integrated data links all 694 animal mature
miRNAs with 287 human miRNAs which are associated
with 359 human diseases referenced in 2,863 Pubmed
articles. This information is classified into five main cat-
egories including information for miRNA, associated
disease, reference, genomic location and target (Table 3).
The integrated resource is the main reference and
preliminary data towards our efforts to develop an
advanced farm and domestic animal disease-associatedmiRNA resource. The preliminary integrated resource is
available at http://agbase.hpc.msstate.edu/cgi-bin/animal_
mirna.cgi.
Application of the integrated resource
We have demonstrated how experimentally confirmed
diabetes type 2-associated miRNA hsa-mir-143-3p can
be used to identify related miRNAs in animals (Figure 7,
Table 2) thus, providing a more focused hypothesis-driven
investigations in animals. We found that the hsa-miR-143
which is located on the right arm (3′) of its pre-miRNA is
highly conserved in pig, horse and dog. The hsa-miR-143-
3p target gene is AKT1 [84] which has 97- 100% sequence
identity with AKT1 found in pig, horse and dog. The bio-
logical processes annotated to AKT1 using Gene ontology
(GO) [85,86] indicate that this gene is involved in similar
processes in all species including, glucose homeostasis,
positive regulation of glucose import, positive regulation
of glycogen biosynthetic process, response to food and
glucose transport (Table 2).
Discussion
One means of identifying diseases before symptoms
appear is through the discovery and utilization of disease-
associated molecular biomarkers. Many biomarker tech-
niques that have been widely applied in human and model
organism studies have not been adequately implemented
in the study of domestic animal diseases. It is now clear
that miRNA play major regulatory role in various disease
processes but financial investment is more committed to
investigate miRNA involvement in human disease more
than any other species (Figure 1). There are several miR-
NAs currently classified as biomarkers for human cancers
[27,42,87-93], cardiovascular [45,46,94,95], and inflamma-
tion [54-57] diseases. Although not experimentally found
Table 1 Human disease miRNA with animal counterparts
Human_homolog MicroRNA family Cow (bta) Chicken (gga) Pig (ssc) Horse (eca) Dog (cfa) Total animal species
hsa-miR-128-3p mir-128 + + + + + 5
hsa-miR-130a-3p mir-130 + + + + + 5
hsa-miR-135a-5p mir-135 + + + + + 5
hsa-miR-148a-3p mir-148 + + + + + 5
hsa-miR-184 mir-184 + + + + + 5
hsa-miR-19a-3p mir-19 + + + + + 5
hsa-miR-193a-5p mir-193 + + + + + 5
hsa-miR-204-5p mir-204 + + + + + 5
hsa-miR-205-5p mir-205 + + + + + 5
hsa-miR-27b-3p mir-27 + + + + + 5
hsa-miR-29b-3p mir-29 + + + + + 5
hsa-miR-30b-5p mir-30 + + + + + 5
hsa-miR-365b-3p mir-365 + + + + + 5
hsa-miR-490-3p mir-490 + + + + + 5
hsa-miR-19b-3p mir-19 + + + + - 4
hsa-miR-193a-3p mir-193 + + + + - 4
hsa-miR-24-3p mir-24 + + + + - 4
hsa-miR-206 mir-1 + + - + + 4
hsa-miR-20a-5p mir-17 + + - + + 4
hsa-miR-190a-5p mir-190 + + - + + 4
hsa-miR-194-5p mir-194 + + - + + 4
hsa-miR-216b-5p mir-216 + + - + + 4
hsa-miR-383-5p mir-383 + + - + + 4
hsa-miR-98-5p let-7 + - + + + 4
hsa-miR-99b-5p mir-10 + - + + + 4
hsa-miR-130b-3p mir-130 + - + + + 4
hsa-miR-148b-3p mir-148 + - + + + 4
hsa-miR-149-5p mir-149 + - + + + 4
hsa-miR-187-3p mir-187 + - + + + 4
hsa-miR-532-5p mir-188 + - + + + 4
hsa-miR-196a-5p mir-196 + - + + + 4
hsa-miR-208b-3p mir-208 + - + + + 4
hsa-miR-92a-3p mir-25 + - + + + 4
hsa-miR-92b-3p mir-25 + - + + + 4
hsa-miR-26a-5p mir-26 + - + + + 4
hsa-miR-151a-5p mir-28 + - + + + 4
hsa-miR-29c-3p mir-29 + - + + + 4
hsa-miR-324-5p mir-324 + - + + + 4
hsa-miR-328-3p mir-328 + - + + + 4
hsa-miR-331-3p mir-331 + - + + + 4
hsa-miR-34a-5p mir-34 + - + + + 4
hsa-miR-361-5p mir-361 + - + + + 4
hsa-miR-376a-3p mir-368 + - + + + 4
hsa-miR-370-3p mir-370 + - + + + 4
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Table 1 Human disease miRNA with animal counterparts (Continued)
hsa-miR-374b-5p mir-374 + - + + + 4
hsa-miR-423-5p mir-423 + - + + + 4
hsa-miR-499a-5p mir-499 + - + + + 4
hsa-miR-628-5p mir-628 + - + + + 4
hsa-miR-708-5p mir-708 + - + + + 4
hsa-miR-885-5p mir-885 + - + + + 4
hsa-miR-146a-5p mir-146 - + + + + 4
hsa-miR-21-5p mir-21 - + + + + 4
hsa-miR-218-5p mir-218 - + + + + 4
hsa-miR-22-3p mir-22 - + + + + 4
hsa-miR-34c-5p mir-34 - + + + + 4
hsa-miR-9-5p mir-9 - + + + + 4
A complete table of all matches is provided in the Additional file 1.
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diseases are also found in domestic animals [96-99].
Advances in knowledge about human disease-associated
miRNAs warrant investigation of similar diseases in
related species.
In this study we used homology approach to generate
a resource that integrates animal miRNA data with hu-
man disease-associated miRNAs. As demonstrated using
hsa-miR-143-3p which has been associated with diabetes
type 2 [84] (Figure 7 and Table 2) it is logical that similar
miRNAs perform comparable functions across related




































Figure 5 Nucleotide substitution rate of pre-miRNAs of HDMACs in ke
indicates pre-miRNA sequences with zero nucleotide substitution rate; red
rate and green bars are pre-miRNA sequences with >5% nucleotide substitin one species may be correlated with homologous
miRNA expression and disease in related species. The
example of diabetes type 2-associated miRNA hsa-miR-
143-3p gave a highlight on how to link disease-associated
elements across species and develop hypothesis-driven
investigation in animals. Integrating all data enabled us to
identify some human disease miRNAs that are found in
more than one animal species (Additional file 1), which
indicates the likelihood of also sharing common diseases.
Having miRNAs targeting similar genes across species
provide clue of functional orthology. As indicated in








  >5% Nucleotide substitution rate
  <5% Nucleotide substitution rate
 0% Nucleotide substitution rate
y domestic animals. For a particular human-animal pair, blue
bars indicates pre-miRNA sequences with <5% nucleotide substitution
ution rate.
Figure 6 Example of phylogenetic analysis of HDMACs pre-miRNAs in the mir-154 family. The branch labels are pre-miRNA IDs prefixed by
abbreviation of species scientific name; hsa (Homo sapiens - human), bta (Bos Taurus - cow), gga (gallus gallus - chicken), ssc (Sus scrofa - pig), eca
(Equine canibus - horse), and cfa (Canis familiaris - dog); followed by numbers that indicate the proportion of evolutionary distance in terms of
nucleotide substitutions per site per unit time, which indicates the changes in sequences when they evolved from a common ancestral sequence.
The alternating background colors (light pink, light green) facilitate visualization and comparison of miRNA species within the cluster.
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mented in nearly 400 Pubmed articles and is associated
with 124 human disease phenotypes and has homologs in
four animals including chicken.
However, not all human miRNA-related diseases may
be relevant to all animals. Manual curation effort to
continue building and updating the animal disease
miRNA resource developed in this study is our long
term process. The relevance of each human miRNA dis-
ease linked to each animal and targeted gene will con-
tinue to be established and integrated in the resource.
Validation of the human disease miRNAs in the animal
context will likely leverage the findings in human at thesame time improve our understanding of their involvement
in the pathogenesis, diagnosis, and prognosis of various
animal diseases.
Conclusions
In this study we have shown that some human disease-
associated miRNAs are well conserved across domestic
animals. Also, human genes targeted by disease-associated
miRNAs are highly conserved in animals. Conservation of
both miRNAs and their target genes across human and
domestic animals provides the likelihood of having func-
tional orthology relationship which may also lead to simi-


















B MFE secondary structure of mir-143 pre-miRNA
hsa-mir-143-3p
Figure 7 Comparative structural analysis of human hsa-miR-143 and its animal orthologs. The multiple sequence alignment (A) shows the
location of the mature miRNA on the 3′ arm of the pre-miRNA. The minimum free energy (MFE) secondary structure (B) of human mir-143 is
compared to that of the animal orthologs and a normalized pre-miRNA consensus sequence. The species are abbreviated by their scientific names;
hsa (Homo sapiens –human), ssc (Sus scrofa - pig), eca (Equine canibus - horse), and cfa (Canis familiaris - dog).















Human hsa-miR-143-3p AKT1 (Confirmed) 480 aa 100 Glucose homeostasis, positive regulation
of glucose import, positive regulation
of glycogen biosynthetic process, response
to food, glucose transport.
Cleavage
Pig ssc-miR-143-3p AKT1 (Predicted) 480 aa 100 Glucose homeostasis, positive regulation
of glucose import, positive regulation of
glycogen biosynthetic process, response
to food, glucose transport.
Cleavage
Horse eca-miR-143 AKT1 (Predicted) 479 aa 98 Glucose homeostasis, positive regulation
of glucose import, positive regulation of
glycogen biosynthetic process, response
to food, glucose transport
Cleavage
Dog cfa-miR-143 AKT1 (Predicted) 479 aa 97 Glucose homeostasis, positive regulation
of glucose import, positive regulation
of glycogen biosynthetic process, response
to food, glucose transport
Cleavage
Over-expression of hsa-miR-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism [83].
*Showing only the biological process GO terms with direct relevance to type 2 diabetes.
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Table 3 Summary of integrated information in the animal
disease-miRNA resource
Information Specific information
MicroRNA 1. Mature miRNA ID
2. Mature miRNA AC






Location 9. Chromosome number
10. Genomic coordinates (start & end)
11. Strand (positive or negative)
Reference 12. Pubmed ID
13. Pubmed Central ID (indicates free articles)
14. Pubmed title
15. Pubmed publication date
Disease 16. Disease phenotype (reported in Pubmed article)
17. Relevance in animal (for non-domestic
animal diseases)
18. OMIM/OMIA disease phenotype name
19. OMIM/OMIA disease phenotype ID
20. Disease Ontology (DO)
21. Tissue/Cell type (source of samples used)
22. Brenda Tissue Ontology (BTO) name
23. BTO ID
24. Method used to associate a disease with a miRNA
Target 25. Gene targeted by the disease miRNA
26. Animal ortholog of targeted gene
27. Reciprocal% identity of target:ortholog
28. Orthology_confidence[0 low,1 high]
The integrated data is availableat http://agbase.hpc.msstate.edu/cgi-bin/
animal_mirna.cgi.
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source, identifying miRNA-related diseases in animals and
utilization of miRNA disease biomarkers in animal and
veterinary research. In the long-term, validating these
human disease miRNAs in domestic animals could iden-
tify new large animal models of diseases and most likely
biomarkers to expedite development of therapeutic mea-
sures for human and animal diseases.
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Additional file 1: Distribution of human disease microRNAs across
animal counterparts. Multiple human diseases and locations are
separated by a pipe (column 3). The (+) or (−) in columns 2–6 indicates
presence or absence of homologous human disease miRNA (column 1)
in the selected animal species.
Additional file 2: Phylogenetic distances of pre-miRNAs of
HDMACs. The data in column 1 & 3 are the pre-miRNA ID for animals
and human, respectively prefixed with abbreviation of species scientific
name i.e. bta (Bos Taurus - cow), gga (gallus gallus - chicken), ssc (Sus
scrofa - pig), eca (Equine canibus - horse), cfa (Canis familiaris - dog),
and hsa (Homo sapiens - human). Column 2 & 4 show the phylogenetic
distances calculated based on nucleotide substitution rate within similar
clusters.
Additional file 3: Sample of disease miRNAs targets and their
animal orthologs. Experimentally verified genes targeted by the disease
miRNAs are manually curated from Pubmed articles and their % identity
with an animal ortholog is generated via Ensembl Biomart [76].
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